Particle.news

Download on the App Store

Stem Cell Grafts Achieve Myelin Repair in Mice, Set Stage for Progressive MS Trial

Following successful animal studies, the RESTORE consortium is poised to launch a first-in-human efficacy trial of induced neural stem cell grafts for progressive multiple sclerosis.

Image
The goal of this research is to see how these therapies may mitigate brain atrophy and slow the progression of MS.Credit: Neuroscience News

Overview

  • Induced neural stem cells differentiated into mature oligodendrocytes and rebuilt myelin sheaths in chronically demyelinated mouse spinal cords.
  • Human iNSC transplants demonstrated long-term survival and safety in models of central nervous system demyelination without adverse effects.
  • Transplanted mouse iNSCs integrated in Olig1−/− lesions and directly generated new exogenous myelin sheaths in a progressive MS model.
  • The RESTORE consortium is creating a patient-focused trial protocol to assess whether iNSC grafts can remyelinate lesions and restore neurological function in people with progressive MS.
  • Current therapies manage progressive MS symptoms but do not halt or reverse neurodegeneration, highlighting the need for remyelination-based approaches.